Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

CNS Pharmaceuticals, Inc. - Common Stock (NQ: CNSP )

0.1400 +0.0322 (+29.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CNS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at BIO CEO & Investor Conference
Via Investor Brand Network
CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference
Via ACCESS Newswire
Study Reveals Insights into How Needed Treatments Can Bypass the Blood-Brain Barrier
Via Investor Brand Network
Chinese Research Team Suggests Common Drug for Blood Pressure Could Treat Invasive Brain Tumor
Via Investor Brand Network
Research Shows Brain Tumors Grow by Hijacking Circadian Clocks
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Host Virtual Analyst & Investor Day on December 11
Via Investor Brand Network
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024
Via ACCESSWIRE
CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results
Via ACCESSWIRE
AI Model Promises New Way to Detect Brain Malignancies
Via Investor Brand Network
Topics Artificial Intelligence Death
Exposures Artificial Intelligence Death
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Presents Progress in Pivotal Study of Berubicin for Glioblastoma Treatment
Via Investor Brand Network
Exposures Product Safety
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Via ACCESSWIRE
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present Berubicin Trial Update at Society for Neuro-Oncology Annual Meeting
Via Investor Brand Network
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)
Via ACCESSWIRE
New Graphene Chip Could Revolutionize Brain Cancer Treatment
Via Investor Brand Network
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment
Via ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances Glioblastoma Treatment with Berubicin Amid Strong Financial Position
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Berubicin’s Potential in Glioblastoma Treatment During KOL Connect Event
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Granted Nasdaq Extension for Compliance
Via Investor Brand Network
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
Via ACCESSWIRE
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment
Via ACCESSWIRE
CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC
Via ACCESSWIRE
CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum
Via ACCESSWIRE
Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG
Via AB Newswire
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures $3 Million in Registered Direct Offering
Via Investor Brand Network
CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Management, Dr. Samuel Goldlust Participate in Virtual Investor KOL Connect Segment
Via Investor Brand Network
Jimmy Carter Survival Thanks to Novel Cancer Immunotherapy Treatment
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum
Via Investor Brand Network
WHO Review Says No Link Between Mobile Phones, Brain-Cancer Development
Via Investor Brand Network
CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.